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to right foot strike. This may indicate a hesitancy to shift weight
from the contralateral limb (left) to the injected limb (right). Asym-
metries were also observed in rats treated with IL1Ra; however,
asymmetry shifts occurred in both directions (Fig. 1). Both groups
demonstrated a strong preference for the contralateral limb on
post-treatment day 2 and 6, spending approximately 10% more
time on the contralateral limb relative to the injected limb. Fur-
thermore, rats treated with IL1Ra exhibited aerial phases where
neither hind limb was in ground contact (Fig. 2). Sensitivity in the
injected limb, detected as lower mechanical withdrawal thresholds,
increased in both groups with no differences between the groups
(Fig. 3).
Conclusions: Rats receiving a unilateral knee injection of hIL1β
overexpressing cells locomoted at higher velocities, used asym-
metric gait with a preference for the uninjected limb, and exhibited
increased mechanical sensitivity. A single treatment with IL1Ra
was associated with more symmetric gaits; however, treatment
with IL1Ra showed little tendency to modify any other measure at
up to 6 days post-treatment. While intra-articular injection of IL1Ra
has therapeutic potential for reversing the effects of IL1-mediated
Figure 3
inﬂammation, these data indicate that a single injection is not
sufﬁcient to restore joint function or reduce heightened sensitivity
associated with IL1β overexpression. This is likely driven by rapid
and efﬁcient IL1Ra clearance from the joint space and motivates
studies of sustained intra-articular delivery of IL1Ra.
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Purpose: New therapies for refractory arthritis pain are needed.
Studies have shown that inﬂammation within joints may cause
peripheral and central sensitization of neurons leading to spon-
taneous joint pain at rest and hyperalgesia with stimulation. In-
ﬂammatory mediators induced by neuropeptide release activate
peripheral nerve receptors. Given this peripheral sensitization we
hypothesize arthritis pain may be treated by intra-articular (IA)
neurotoxins. Efﬁcacy of IA botulinum toxin (BoNT) Type A for re-
fractory arthritis pain, and in murine models has recently been
reported, prompting interest in screening other botulinum toxins
that may prove more effective for arthritis pain. Currently BoNT
A and BoNT Type B are the best characterized and most used
clinically. BoNT B may produce greater pain relief and may be
effective in different types of pain than BoNT A. We hypothesized
that BoNT B would reduce chronic arthritic knee pain, testing this
in a murine model of chronic degenerative arthritis
Methods: Chronic arthritis was produced in C57Bl6 mice by IA
injection of 10 IU Collagenase in 10 μl NS in the left knee peaking
at 4 weeks. BoNT B (MYOBLOC) 0.02 IU in 5 μl of NS was given
IA in the left knee 3 days before testing. Normal right knee served
as internal control. Mice were studied before, after induction of
arthritis and after IA BoNT B. Video gait analysis performed using
Treadscan™ video gait analysis system hardware and software.
In this system lameness was quantiﬁed as the standard deviation
of stance to stride ratio (STA/STR). Knees were examined for
bony swelling indicative of arthritis. Evoked pain behavior was
measured by tallying ﬁghts + vocalizations/1 min in response to
repeated ﬁrm palpation of the knee by a single examiner trained
for consistency and precision. Gait and strength were observed
visually and graded semi-quantitatively as a consensus score
among 3 examiners. Strength was measured as ability to grasp
and cling. Student’s t-test used for statistical comparisons.
Results: Swelling, visual and video gait analysis revealed signif-
icant alterations following IA collagenase, indicating induction of
arthritis (swelling P= 0.0016, gait P= 0.0081, variability of STA/STR
P=0.0128). Evoked pain behaviors increased with arthritis, but
were not statistically signiﬁcant (p=0.3274). Signiﬁcant improve-
ment in visual gait scores (p=0.0045) and video gait analysis
STA/STR variability (p < 0.0001) were noted following IA BoNT
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B. Stride frequency also trended towards normalization post IA
BoNT B, approaching statistical signiﬁcance (p= 0.0624). Evoked
pain behaviors improved following IA BoNT B, but did not reach
statistical signiﬁcance. No weakness of the hindlimb was noted
following IA BoNT B (grasp p= 0.7872 cling p=0.5433)
Conclusions: Chronic degenerative arthritis pain can be quan-
titated in a murine model using visual and computerized gait
analysis, and joint tenderness scores. Visual and computerized
gait analysis both showed a signiﬁcant impairment in gait in
arthritic mice, improving after IA BoNT B suggesting a substantial
analgesic effect. Evoked pain responses increased overall with
arthritis, decreasing with IA BoNT B, but not reaching statistical
signiﬁcance. Further studies are underway to expand on these
results.
These ﬁndings support the hypothesis that chronic arthritis pain
may be ampliﬁed by neuropeptide release in the periphery due to
efferent neurogenic signals. Interruption of neuropeptide release
by IA BoNT B appeared to decrease pain responses in the joint
and improve gait abnormalities. IA BoNT B was safe: no increased
joint inﬂammation nor weakness of limb was noted. These results
support further investigation of this novel approach to treatment of
arthritis pain with IA neurotoxin
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Purpose: Interleukin-17 (IL17) is a novel T helper cell-associated
cytokine recently found to be present at high levels in both her-
niated and degenerate tissues of the intervertebral disc (IVD).
IL17 and other Th17-related cytokines are known regulators of
inﬂammation in multiple autoimmune diseases, suggesting their
potential involvement in regulating IVD pathology. The objective
of this study is to determine the effects of IL17 and a potent
co-stimulant, interferon (IFNγ) on human cells from degenerated
IVD sources. An ability for IL17 with IFNγ to promote inﬂammatory
cytokine and mediator expression was assessed in IVD cells and
compared to effects of another potent pro-inﬂammatory cytokine,
TNFα.
Methods: Human IVD cells were isolated from to-be discarded
tissues from patients undergoing surgery for degenerative IVD
pathology (n=4). Cells of the anulus ﬁbrosus (AF) region were
plated at 25,000 cells per well (96-well plates, n=4 wells per
group) and overlaid with 150 μL of medium overnight (5% CO2,
37°C). Media was then replaced with new media supplemented
with one of the following cytokine concentrations: media alone
Abstract 498 – Figure 1. NOx (LEFT) and PGE2 (RIGHT) production by AF cells from 4 degenerative human tissue samples after treatment with control media or
media with IL-17, IFNγ, or both IL-17 and IFNγ. The values for the media control only were indicated as dotted horizontal lines.
(control), TNFα (25 ng/mL), IL17 (10 ng/mL), IFNγ (200 U/mL)
or both IL17 and IFNγ. After 72 hours, the supernatant was
evaluated for release of nitric oxide (NOx, Griess reaction) and
prostaglandin E2 (PGE2, ELISA). One-way ANOVA and post-hoc
Dunn’s analysis evaluated differences amongst treatment groups
for NOx and PGE2 release (p=0.05).
Results: Stimulation of AF cells with IL17 or IFNγ alone did
change NOx levels from control values; however, a signiﬁcant
variability in NOx responses was observed across human subjects
(Figure 1 left). In the presence of IFNγ costimulant, IL17 induced
average 2-fold increase in NOx production above that of IL17
alone (IL17: average NOx = 22 μM, IL17 + IFNγ: NOx = 45 μM,
Figure 1 left). In contrast, stimulation with IL17 alone led to a
signiﬁcant elevation in PGE2 levels in all 4 samples (average 14-
fold increase, Figure 1 right). As for the NOx result, co-stimulation
with IL17 and IFNγ led to a large increase in PGE2 release, more
than 24-fold over control values (Figure 1 right, IL17 + IFNγ PGE2
release = 1.36 ng/ml; Control PGE2 release = 0.06 ng/ml). In
general, the induction of NOx and PGE2 release by IL17 and
IFNγ co-stimulation was signiﬁcantly larger than that due to TNFα
stimulation, for which few changes in NOx and a 10-fold increase
in PGE2 was observed.
Conclusions: The results of this study demonstrate that degen-
erative human IVD cells may respond to IL17 stimulation with
increased production of the inﬂammatory mediators, PGE2 and
NOx, with a more robust effect observed in the presence of IFNγ.
Degenerative and herniated IVD explants are known to contain
IFNγ, and IFNγ is known to act synergistically with IL17 to promote
release of inﬂammatory mediators in other cell types. This work
demonstrates that the responsiveness of IVD cells to IL17 and
IFNγ is consistent with other cell types, and suggests a potential
role for these cytokines in contributing to IVD pathology.
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Purpose: We hypothesize that osteoarthritis (OA) pain-associated
bone marrow lesions, effusion, and synovitis are driven patho-
physiologically by VEGF mediated increases in vascular perme-
ability, and that local inhibition of VEGF will alleviate OA pain
by decreasing incidence and severity of these abnormalities. Our
previous work demonstrated that VEGF inhibition using virally de-
livered soluble Flt receptor (sFlt) decreased synovitis and pain
marker expression in a rabbit OA model. In an effort to move
